Remimazolam Tosilate + Propofol
Phase 2Completed 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
General Anesthesia
Conditions
General Anesthesia
Trial Timeline
Dec 1, 2014 → Aug 1, 2015
NCT ID
NCT02406872About Remimazolam Tosilate + Propofol
Remimazolam Tosilate + Propofol is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for General Anesthesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02406872. Target conditions include General Anesthesia.
What happened to similar drugs?
14 of 20 similar drugs in General Anesthesia were approved
Approved (14) Terminated (3) Active (5)
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04400201 | Phase 3 | Completed |
| NCT03921775 | Phase 3 | Completed |
| NCT03779061 | Phase 3 | Completed |
| NCT03425474 | Phase 3 | Completed |
| NCT03003884 | Phase 2 | Completed |
| NCT02406872 | Phase 2 | Completed |
Competing Products
20 competing products in General Anesthesia